Polyrizon Ltd. (PLRZ)
NASDAQ: PLRZ · Real-Time Price · USD
10.83
+0.08 (0.74%)
At close: Apr 10, 2026, 4:00 PM EDT
11.14
+0.31 (2.86%)
After-hours: Apr 10, 2026, 7:29 PM EDT
Polyrizon Employees
As of December 31, 2025, Polyrizon had 4 total employees, including 2 full-time and 4 part-time employees. The number of employees decreased by 2 or -33.33% compared to the previous year.
Employees
4
Change (1Y)
-2
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$833,750
Market Cap
17.57M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 4 | -2 | -33.33% | 2 | 2 |
| Dec 31, 2024 | 6 | - | - | 2 | 4 |
Related Stocks
| Company Name | Employees |
|---|---|
| Curis | 24 |
| Citius Pharmaceuticals | 23 |
| SeaStar Medical Holding | 19 |
| Lipocine | 14 |
| Genenta Science | 13 |
| Cocrystal Pharma | 10 |
| VYNE Therapeutics | 10 |
| Allarity Therapeutics | 8 |
PLRZ News
- 3 days ago - Polyrizon Ltd. Announces Closing of $3.5 Million Registered Direct and Private Placements - GlobeNewsWire
- 16 days ago - Polyrizon Provides 2025 and Recent Highlights - GlobeNewsWire
- 17 days ago - Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - GlobeNewsWire
- 18 days ago - Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications - GlobeNewsWire
- 25 days ago - Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program - GlobeNewsWire
- 4 weeks ago - Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - GlobeNewsWire
- 6 weeks ago - Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product - GlobeNewsWire
- 7 weeks ago - Moonage Media Spotlights Polyrizon (Nasdaq: PLRZ): Unveils NASARIX™, Drug-Free Allergy Blocker - PRNewsWire